Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bydureon in Type 2 Diabetes Mellitus
NCT00103935Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2005
- Primary completion
- Oct 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of exenatide extended-release in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Feb 2005; status: completed.
02
Drugs
exenatide extended-release
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00103935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00103935.